Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2

NCT05367635 is registered in ClinicalTrials.gov with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05367635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05367635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2
Lead sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 16, 2022
Completion date
June 30, 2028
Enrollment
246 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors